...Jussane Oliveira Vieira; João Bosco Pesquero; Afonso Celso Pinto Nazário Introduction: Breast cancer is the most prevalent cancer in women worldwide, and neoadjuvant chemotherapy is a favored method for achieving pathologic complete response (pCR). The TP53 gene is involved in inducing the response...

...Omar Abdul Hameed Ali; Ahmed Elhaj Background: Because of resource constrains in sub-Saharan African countries, breast-conserving surgery (BCS) has no role in patients with locally advanced breast cancer (LABC) following neoadjuvant chemotherapy (NACT), and mastectomy remains the standard surgical...

...Sabin Goktas Aydin; Ahmet Bilici; Omer Fatih Olmez; Basak B. Oven; Ozgur Acikgoz; Tansel Cakir; Pelin Basim; Asli Cakir; Yasin Kutlu; Jamshid Hamdard Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response...

...Moritz Dimpfl; Doris Mayr; Elisa Schmoeckel; Tom Degenhardt; Tanja K. Eggersmann; Nadia Harbeck; Rachel Wuerstlein Introduction: This project aimed to identify the frequency of a switch of hormone receptor (HR) and/or HER2 status after neoadjuvant chemotherapy (NAC) for early breast cancer. Methods...

...Peixian Chen; Chuan Wang; Ruiliang Lu; Ruilin Pan; Lewei Zhu; Dan Zhou; Guolin Ye Introduction: Currently, the accurate evaluation and prediction of response to neoadjuvant chemotherapy (NAC) remains a great challenge. We developed several multivariate models based on baseline imaging features...

... Cardoso Background: Axillary staging in patients with complete response after neoadjuvant chemotherapy (NAC) is still controversial. Our objective was to test tattoo alone and subsequentially tattoo plus clip as markers in the targeted axillary dissection of ycN0 patients. Methods: Prospective cohort...

...Lukas Dostalek; Andrej Cerny; Petra Saskova; David Pavlista Introduction: Axillary dissection has little diagnostic and therapeutic benefit in node-positive breast cancer patients in whom axillary disease has been completely eradicated after neoadjuvant chemotherapy (ypN0). We sought to assess...

...George Kirkilesis; Anastasia Constantinidou; Michalis Kontos Introduction: Targeted axillary dissection (TAD) has been proposed as an alternative method for the staging of patients with node-positive breast cancer who undergo neoadjuvant chemotherapy. However, not much is known yet about the false...

...). Objective: To investigated the prognostic roles of NLR and sTILs and their rela-tionship of TNBC patients treated with neoadjuvant chemotherapy (NAC). Methods: The clinical data of 170 patients with locally advanced TNBC who received NAC from January 2010 to December 2014 were collected. The difference...

... and/or ovarian cancer may therefore react differently in relation to pCR and prognosis, and this is investigated in this study. Patients and Methods: Breast cancer patients were identified from a clinical breast cancer registry. The study subjects had been treated with neoadjuvant chemotherapy from 2001 to 2018...

...Christiane Matuschek; Carolin Nestle-Kraemling; Thorsten Kühn; Tanja Fehm; Edwin Bölke; Stefanie Corradini; Gerd Fastner; Kitti Maas; Clemens Seidel; Wilfried Budach Background: The international standard of care for the treatment of high-risk breast cancer (BC) consists of neoadjuvant chemotherapy...

... node involvement, and its pathological response to neoadjuvant chemotherapy is rarely reported. Case Presentation: Pure mucinous breast carcinoma in a 25-year-old female was treated with neoadjuvant chemotherapy every 3 weeks for 8 cycles. After the fifth cycle, the mass size showed no change. We...

... , Semiglazov   V , Manikhas   A , Lluch   A , Tjulandin   S , et al.   Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled...

... margins. Methods: 80 patients with invasive breast cancer receiving BCS after neoadjuvant chemotherapy were included in this non-randomized case-control study. 40 patients with specimen radiography performed in a standard approach (control group) were compared to 40 patients with use of a radiopaque...

..., instructions or products referred to in the content or advertisements. Sentinel lymph node Neoadjuvant chemotherapy Axillary dissection Nomogram The optimal timing for sentinel lymph node biopsy (SLNB) in the setting of primary systemic therapy (PST) is still a matter of debate. Recent studies...

...Thorsten Kühn; Jean-Marc Classe; Oreste David Gentilini; Corrado Tinterri; Florentia Peintinger; Jana de Boniface Summary Axillary surgery has undergone considerable changes in recent years, especially in relation to patients who undergo neoadjuvant chemotherapy (NACT). Due to constantly decreasing...

...-negative breast cancer (TNBC) and human epidermal growth factor receptor 2(HER2)-positive breast cancer who do not have a pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) have a very poor prognosis. Tumor-infiltrating lymphocytes (TILs) have been identified as a predictive marker...

... such as the triple-negative (TN) subtype adds to this menace. Androgen receptor (AR) is emerging as a new biological marker. The aim of this study was to examine the prevalence of AR with relation to different BC subtypes, and its role in predicting response to neoadjuvant chemotherapy. Methods: 116 cases...

...Xiaodong Zhou; Yujie Li Summary Background: Breast-conserving surgery (BCS) in patients with large tumors shrunk by neoadjuvant chemotherapy (NCT) remains controversial. We conducted a meta-analysis to evaluate the local recurrence rates in locally advanced breast cancer (LABC) patients receiving...

..., antibody therapy, and radiotherapy. The patient received neoadjuvant chemotherapy with paclitaxel 80 mg/m 2 weekly for 12 cycles, followed by 4 cycles of epirubicin and cyclophosphamide (90/600 mg/m 2 ) every 3 weeks. Complete clinical response was seen after preoperative chemotherapy. After delivery...